About Us
Contineum Therapeutics is a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS) and chronic pain, and PIPE-307, is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis (RRMS) and major depressive disorder. Contineum Therapeutics is also advancing discovery efforts targeting additional NI&I indications where the Company’s internally-discovered molecules and approach may have therapeutic potential.
